EG-1 siRNA lentivirus

EG-1 siRNA lentivirus is an experimental gene therapy agent designed to silence the expression of the Early Gene 1 (EG-1) protein, also known as Proliferation-associated protein 2G4 (PA2G4) or ErbB3-binding protein 1 (EBP1). EG-1 is a gene product significantly elevated in human breast cancer tissues that stimulates cellular proliferation. The therapeutic agent utilizes a lentiviral vector to deliver small interfering RNA (siRNA) or short hairpin RNA (shRNA) sequences specific to EG-1 mRNA. Upon entering the target cells, the siRNA triggers the RNA interference (RNAi) pathway, leading to the degradation of EG-1 transcripts and a subsequent reduction in EG-1 protein levels. Preclinical research has shown that this knockdown effectively inhibits the growth of both estrogen receptor (ER)-positive (MCF-7) and ER-negative (MDA-MB-231) breast cancer cells in vitro and reduces tumor progression in xenograft mouse models.

Other names

siRNA-EG1 lentivirussiRNA-EG-1 lentivirussiRNA-EG 1 lentivirusEG-1 shRNA lentivirusEG1 shRNA lentivirusEG 1 shRNA lentivirus